Buyers of distressed assets find much to like about this market. This article looks at what Bruce Berkowitz, David Winters, Matthew McLennan of First Eagle Global Fund, Marty Whitman, and Shawn Tumulty of the Mutual Discovery Fund are looking for in this distressed market.

Investors have long enjoyed a love-hate relationship with pharmaceutical stocks. This sector is unique in that their products are effectively scheduled for obsolescence via expiring patents. As such, a pharmaceutical company's pipeline of new products is just as important, or maybe more important, than the company's current offerings.

When investors purchase their initial position in a stock, it is usually after their most rigorous research. Once a stock is in their portfolio, some investors relax on the research for subsequent purchases. Each and every time you purchase a stock, you should run it through the same process as if you were buying it for the first time.

The typical dividend aristocrat is a mature company with wide moat that has weathered the storms of many boom and bust cycles while continuing to increase dividend payments to shareholders. These companies as well as the dividend champions are the cornerstone to my dividend strategy.

Floyd Brown says there are five pharmaceutical companies offering outstanding dividend yields in a growing sector. And with most negative sentiment already priced into the stocks, downside risk is limited…

A closer look at GMO’s 7-year asset class expected returns.

The company is a dividend aristocrat as well as a component of the S&P 500 and Dow Jones Industrials indexes. It has been increasing its dividends for the past 41 consecutive years. From 1998 up until 2007 this dividend growth stock has delivered an annual average total return of 1.1 % to its shareholders. The stock has lost more than 63% from its all-time-high of $50 in 1999 however.

Another strong play from medical stock expert Rob Fannon.

The Magic Formula screen is not just for Joel Greenblatt's strategy. This article examines why it also lends well to a dividend based, income investing strategy.

So how can you turn a profit in this turbulent sector? By investing in contract research organisations, or CROs, says biotech expert Rob Fannon. When the big pharmaceutical companies outsource research to CROs they get paid whether or not the new drugs ever make it to market.

Fortune lists 40 stocks on which a person can retire. The list includes eight stocks they label as "deep value."

A roundup of last week's stock market related blog posts hosted at Fat Pitch Financials.

Joe Ponzio explores Phil Fisher's second question by looking at two examples.

The 30 stocks in the Dow Jones Industrials are trading for 82% of Morningstar.com's estimated fair value, which makes the Dow an undervalued 5-star market. Eleven of the 30 industrials are undervalued 5-star stocks, according to Morningstar.

A review of the performance of the Fat Pitch Financials Portfolio for the first quarter of 2008.